related documents
- A Phase II Study of Accelerated Hypofractionated 3-Dimensional Conformal Radiotherapy for Inoperable T1-3 N0 M0 Non-Small Cell Lung Cancer: NCIC CTG BR.25 Conferences
- First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status Conferences
- Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC) Conferences
- Referral of Suspected Lung Cancer by Family Physicians and Other Primary Care Providers: A Clinical Practice Guideline Conferences
- Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC) Conferences